Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Raises $14.5M as Part of Series D Financing

Premium

By Julia Karow

Complete Genomics said in a filing with the Securities and Exchange Commission last week that it has sold $14.49 million in securities.

CEO Cliff Reid told In Sequence by e-mail today that the amount raised in the sale represents "a portion" of the company's Series D financing, which is not yet complete. He declined to provide further details.

According to the "Form D" filing, which the company filed July 2 as an amendment to a prior filing, Complete Genomics has sold $14.49 million in debt, options, warrants, and securities. The filing lists Feb. 13 as the date of first sale.

The document also notes that Complete is not making its securities offering "in connection with a business combination transaction, such as a merger, acquisition, or exchange offer."

The company, which plans to launch a human whole-genome sequencing service for research organizations this summer, revealed in April that it had to implement cost-cutting measures because of a delay in its Series D financing (see In Sequence 4/14/2009).

Last month, Reid said the firm plans to announce news regarding its service and fundraising activities this month (see In Sequence 6/16/2009).

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.